Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations

Trial Profile

Open-Label, Intra Subject, Dose Escalation (Part 1) Followed by Randomized, Double Blind, Placebo Controlled (Part 2) Trial of Topical VT30 in Pts With Venous, Lymphatic or Mixed Malformations Associated With PIK3CA or TEK Genetic Mutations

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VT 30 (Primary)
  • Indications Vascular skin diseases
  • Focus Adverse reactions; First in man
  • Sponsors Venthera

Most Recent Events

  • 01 Aug 2022 Status changed from recruiting to discontinued.
  • 10 Jun 2022 According to a BridgeBio Pharma media release, data from this trial are being shared in a virtual presentation to the International Society for the Study of Vascular Anomalies (ISSVA) 2022.
  • 10 Jun 2022 Preliminary results from phase 1b study published in the BridgeBio Pharma Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top